Young, NS, Kaufman, DW. The epidemiology of acquired aplastic anemia. Haematologica. 2008; 93(4):489–492.Google Scholar

Zaimoku, Y, Takamatsu, H, Hosomichi, K, Ozawa, T, Nakagawa, N, Imi, T, et al. Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. Blood. 2017; 129(21):2908–2916.Google Scholar

Babushok, DV, Duke, JL, Xie, HM, Stanley, N, Atienza, J, Perdigones, N, et al. Somatic HLA mutations expose the role of class I-mediated autoimmunity in aplastic anemia and its clonal complications. Blood Adv. 2017; 1:1900–1910.CrossRefGoogle ScholarPubMed

Nakao, S, Takamatsu, H, Chuhjo, T, Ueda, M, Shiobara, S, Matsuda, T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994; 84(12):4257–4261.CrossRefGoogle ScholarPubMed

Young, NS, Calado, RT, Scheinberg, P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006; 108(8):2509–2519.CrossRefGoogle ScholarPubMed

Ehrlich, P. Uber einen Fall von Anamie mit Bemerkungen uber regenerative Veranderungen des Knochenmarks. Charite-Annalen. 1888; 13:300.Google Scholar

Pegg, DE, Fleming, WJ, Compston, N. A case of aplastic anaemia treated by isologous bone marrow infusion. Postgrad Med J. 1964; 40:213–216.Google Scholar

Thomas, ED, Storb, R, Giblett, ER, Longpre, B, Weiden, PL, Fefer, A, et al. Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol. 1976; 4(2):97–102.Google Scholar

Ascensao, J, Pahwa, R, Kagan, W, Hansen, J, Moore, M, Good, R. Aplastic anaemia: evidence for an immunological mechanism. Lancet. 1976; 1(7961):669–671.Google Scholar

Dunn, DE, Tanawattanacharoen, P, Boccuni, P, Nagakura, S, Green, SW, Kirby, MR, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999; 131(6):401–408.CrossRefGoogle ScholarPubMed

Katagiri, T, Sato-Otsubo, A, Kashiwase, K, Morishima, S, Sato, Y, Mori, Y, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011; 118(25):6601–9660.CrossRefGoogle ScholarPubMed

Socie, G, Rosenfeld, S, Frickhofen, N, Gluckman, E, Tichelli, A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000; 37(1):91–101.CrossRefGoogle ScholarPubMed

Gupta, V, Eapen, M, Brazauskas, R, Carreras, J, Aljurf, M, Gale, RP, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010; 95(12):2119–2125.Google Scholar

Locasciulli, A, Oneto, R, Bacigalupo, A, Socie, G, Korthof, E, Bekassy, A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007; 92(1):11–18.CrossRefGoogle ScholarPubMed

Storb, R, Etzioni, R, Anasetti, C, Appelbaum, FR, Buckner, CD, Bensinger, W, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994; 84(3):941–949.CrossRefGoogle ScholarPubMed

Maury, S, Bacigalupo, A, Anderlini, P, Aljurf, M, Marsh, J, Socie, G, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009; 94(9):1312–1315.Google Scholar

Bacigalupo, A, Socie, G, Schrezenmeier, H, Tichelli, A, Locasciulli, A, Fuehrer, M, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica. 2012; 97(8):1142–1148.Google Scholar

Bacigalupo, A, Marsh, JC. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18–40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant. 2013; 48(2):198–200.Google Scholar

DeZern, AE, Zahurak, M, Symons, H, Cooke, K, Jones, RJ, Brodsky, RA. Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2017; 23(3):498–504.Google Scholar

Esteves, I, Bonfim, C, Pasquini, R, Funke, V, Pereira, NF, Rocha, V, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant. 2015; 50(5):685–689.Google Scholar

Frickhofen, N, Kaltwasser, JP, Schrezenmeier, H, Raghavachar, A, Vogt, HG, Herrmann, F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991; 324(19):1297–1304.Google Scholar

Scheinberg, P, Nunez, O, Weinstein, B, Biancotto, A, Wu, CO, Young, NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011; 365(5):430–438.CrossRefGoogle ScholarPubMed

Hochsmann, B, Moicean, A, Risitano, A, Ljungman, P, Schrezenmeier, H. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant. 2013; 48(2):168–73.Google Scholar

Young, NS, Bacigalupo, A, Marsh, JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010; 16(1 Suppl):S119–125.CrossRefGoogle ScholarPubMed

Saracco, P, Quarello, P, Iori, AP, Zecca, M, Longoni, D, Svahn, J, et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol. 2008; 140(2):197–205.Google Scholar

Townsley, DM, Scheinberg, P, Winkler, T, Desmond, R, Dumitriu, B, Rios, O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017; 376(16):1540–1550.Google Scholar

Fureder, W, Valent, P. Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. Leuk Lymphoma. 2011; 52(8):1435–1445.Google Scholar

Shahani, S, Braga-Basaria, M, Maggio, M, Basaria, S. Androgens and erythropoiesis: past and present. J Endocrinol Invest. 2009; 32(8):704–716.Google Scholar

Olnes, MJ, Scheinberg, P, Calvo, KR, Desmond, R, Tang, Y, Dumitriu, B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012; 367(1):11–19.Google Scholar

Desmond, R, Townsley, DM, Dumitriu, B, Olnes, MJ, Scheinberg, P, Bevans, M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014; 123(12):1818–1825.Google Scholar

Sawada, K, Hirokawa, M, Fujishima, N. Diagnosis and management of acquired pure red cell aplasia. Hematol Oncol Clin North Am. 2009; 23(2):249–259.Google Scholar

Brown, KE, Anderson, SM, Young, NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science. 1993; 262(5130):114–117.CrossRefGoogle ScholarPubMed

Macdougall, IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant. 2005; 20 Suppl 4:iv9–15.Google Scholar

Bolan, CD, Leitman, SF, Griffith, LM, Wesley, RA, Procter, JL, Stroncek, DF, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001; 98(6):1687–1694.Google Scholar

Kurtzman, G, Frickhofen, N, Kimball, J, Jenkins, DW, Nienhuis, AW, Young, NS. Pure red-cell aplasia of 10 years’ duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med. 1989; 321(8):519–523.Google Scholar

Sawada, K, Fujishima, N, Hirokawa, M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008; 142(4):505–514.CrossRefGoogle ScholarPubMed

Macdougall, IC, Rossert, J, Casadevall, N, Stead, RB, Duliege, AM, Froissart, M, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009; 361(19):1848–1855.CrossRefGoogle ScholarPubMed

Clark, DA, Dessypris, EN, Krantz, SB. Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood. 1984; 63(2):277–286.CrossRefGoogle ScholarPubMed

Sawada, K, Hirokawa, M, Fujishima, N, Teramura, M, Bessho, M, Dan, K, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica. 2007; 92(8):1021–1028.Google Scholar

Risitano, AM, Selleri, C, Serio, B, Torelli, GF, Kulagin, A, Maury, S, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol. 2010; 148(5):791–796.Google Scholar

Hillmen, P, Lewis, SM, Bessler, M, Luzzatto, L, Dacie, JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995; 333:1253–1258.Google Scholar

Socie, G, Mary, JY, de Gramont, A, Rio, B, Leporrier, M, Rose, C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996 Aug 31; 348(9027):573–577.Google Scholar

Moyo, VM, Mukhina, GL, Garrett, ES, Brodsky, RA. Natural history of paroxysmal nocturnal hemoglobinuria using modern diagnostic assays. Brit J Haematol. 2004; 126:133–138.CrossRefGoogle ScholarPubMed

Brodsky, RA. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med. 2008 Apr 15; 148(8):587–595.Google Scholar

Miyata, T, Takeda, J, Iida, Y, Yamada, N, Inoue, N, Takahashi, M, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993; 259:1318–1320.Google Scholar

Miyata, T, Yamada, N, Iida, Y, Nishimura, J, Takeda, J, Kitani, T, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994; 330:249–255.CrossRefGoogle ScholarPubMed

Nagarajan, S, Brodsky, R, Young, NS, Medof, ME. Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia. Blood. 1995; 86:4656–4661.Google Scholar

Mukhina, GL, Buckley, JT, Barber, JP, Jones, RJ, Brodsky, RA. Multilineage glycosylphosphatidylinositol anchor deficient hematopoiesis in untreated aplastic anemia. Br J Haematol. 2001; 115:476–482.Google Scholar

Luzzatto, L, Bessler, M, Rotoli, B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: A blessing in disguise? Cell. 1997; 88(January 10):1–4.CrossRefGoogle ScholarPubMed

Medof, ME, Kinoshita, T, Nussenzweig, V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984; 160:1558–1578.CrossRefGoogle ScholarPubMed

Rollins, SA, Sims, PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol. 1990 May 1; 144(9):3478–3483.Google Scholar

Rother, RP, Bell, L, Hillmen, P, Gladwin, MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005 Apr 6; 293(13):1653–1662.Google Scholar

Hall, SE, Rosse, WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood. 1996; 87:5332–5340.Google Scholar

Borowitz, MJ, Craig, FE, DiGiuseppe, JA, Illingworth, AJ, Rosse, W, Sutherland, DR, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2010;78(4):211–230.Google Scholar

Brodsky, RA, Mukhina, GL, Nelson, KL, Lawrence, TS, Jones, RJ, Buckley, JT. Resistance of paroxysmal nocturnal hemoglobinuria cells to the glycosylphosphatidylinositol-binding toxin aerolysin. Blood. 1999; 93(5):1749–1756.CrossRefGoogle Scholar

Brodsky, RA, Mukhina, GL, Li, S, Nelson, KL, Chiurazzi, PL, Buckley, JT, et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol. 2000 Sep;114(3):459–466.Google Scholar

Araten, DJ, Nafa, K, Pakdeesuwan, K, Luzzatto, L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA. 1999 Apr 27; 96(9):5209–5214.Google Scholar

Hu, R, Mukhina, GL, Piantadosi, S, Barber, JP, Jones, RJ, Brodsky, RA. PIG-A mutations in normal hematopoiesis. Blood. 2005 May 15; 105(10):3848–3854.Google Scholar

Pu, JJ, Hu, R, Mukhina, GL, Carraway, HE, McDevitt, MA, Brodsky, RA. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. Haematologica. 2012; 97(8):1225–1233.Google Scholar

Pu, JJ, Mukhina, G, Wang, H, Savage, WJ, Brodsky, RA. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. Eur J Haematol. 2011 Jul;87(1):37–45.CrossRefGoogle ScholarPubMed

Wiedmer, T, Hall, SE, Ortel, TL, Kane, WH, Rosse, WF, Sims, PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993; 82(4):1192–1196.CrossRefGoogle ScholarPubMed

Hugel, B, Socie, G, Vu, T, Toti, F, Gluckman, E, Freyssinet, JM, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999 May 15; 93(10):3451–3456.Google Scholar

Ploug, M, Plesner, T, Ronne, E, Ellis, V, Hoyer-Hansen, G, Hansen, NE, et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood. 1992 Mar 15; 79(6):1447–1455.CrossRefGoogle ScholarPubMed

Maroney, SA, Cunningham, AC, Ferrel, J, Hu, R, Haberichter, S, Mansbach, CM, et al. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost. 2006 May;4(5):1114–1124.Google Scholar

Hillmen, P, Elebute, M, Kelly, R, Urbano-Ispizua, A, Hill, A, Rother, RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010 Aug;85(8):553–559.Google Scholar

Hillmen, P, Young, NS, Schubert, J, Brodsky, RA, Socie, G, Muus, P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006 Sep 21; 355(12):1233–1243.Google Scholar

Brodsky, RA, Young, NS, Antonioli, E, Risitano, AM, Schrezenmeier, H, Schubert, J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008 Feb 15; 111(4):1840–1847.Google Scholar

Hillmen, P, Muus, P, Duhrsen, U, Risitano, AM, Schubert, J, Young, NS, et al. The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal hemoglobinuria (abstract). Blood. 2006; 106:40a–41a.Google Scholar

Saso, R, Marsh, J, Cevreska, L, Szer, J, Gale, RP, Rowlings, PA, et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1999 Feb;104(2):392–396.Google Scholar

Suenaga, K, Kanda, Y, Niiya, H, Nakai, K, Saito, T, Saito, A, et al. Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria. Exp Hematol. 2001 May;29(5):639–642.Google Scholar

Brodsky, RA, Luznik, L, Bolanos-Meade, J, Leffell, MS, Jones, RJ, Fuchs, EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008 Oct;42(8):523–527.CrossRefGoogle ScholarPubMed

Diamond, LK, Blackfan, KD. Hypoplastic anemia. Am J Dis Child. 1938; 15:307.Google Scholar

Lipton, JM, Ellis, SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am. 2009; 23(2):261–282.CrossRefGoogle ScholarPubMed

Narla, A, Ebert, BL. Ribosomopathies: human disorders of ribosome dysfunction. Blood. 2010; 115(16):3196–205.Google Scholar

Sankaran, V, Chazvinian, R, Do, R, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012; 122(7):2439–2443.CrossRefGoogle ScholarPubMed

Fumagalli, S, Thomas, G. The role of p53 in ribosomopathies. Semin Hematol. 2011; 48(2):97–105.Google Scholar

Narla, A, Vlachos, A, Nathan, DG. Diamond Blackfan anemia treatment: past, present, and future. Semin Hematol. 2011; 48(2):117–123.Google Scholar

Zinsser, F. Atrophia cutis reticularis cum pigmentations, dystrophia unguium et leukoplakis oris (Poikioodermia atrophicans vascularis Jacobi). Ikonogr. Dermatol. 1910; 5:219–233.Google Scholar

Savage, SA, Alter, BP. Dyskeratosis congenita. Hematol Oncol Clin North Am. 2009; 23(2):215–231.CrossRefGoogle ScholarPubMed

Ballew, BJ, Savage, SA. Updates on the biology and management of dyskeratosis congenital and related telomere biology disorders. Expert Rev Hematol. 2013; 6(3):327–337.CrossRefGoogle ScholarPubMed

Alter, B, Giri, N, Savage, S, et al. Malignancies and survival patters in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol. 2010; 150(2):179–188.Google Scholar

Lobitz, S, Velleuer, E. Guido Fanconi: a jack of all trades. Nat Rev Cancer. 2006; 6(11):893–898.Google Scholar

Bagby, GC, Alter, BP. Fanconi anemia. Semin Hematol. 2006; 43(3):147–156.CrossRefGoogle ScholarPubMed

Garaycoechea, J, Patel, KJ. Why does the bone marrow fail in Fanconi anemia. Blood. 2014; 123(1):26–34.Google Scholar

Kupfer, GM. Fanconi anemia: a signal transduction and DNA repair pathway. Yale J Biol Med. 2013; 60(6):1291–1310.Google Scholar

Kee, Y, D’Andrea, D. Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest. 2012; 122(11):3799–3806.Google Scholar

Schwachman, H, Diamond, LK, Oski, FA, Khaw, KT. The syndrome of pancreatic insufficiency and bone marrow dysfunction. J Pediatr. 1964; 65:645–663.Google Scholar

Myers, KC, Davies, SM, Shimamura, A. Clinical and molecular pathophysiology of Schwachman-Diamond syndrome: an update. Hematol Oncol Clin N Am. 2013;(27):117–128.CrossRefGoogle ScholarPubMed

Boocock, GR, Morrioson, JA, Popvic, M, et al. Mutations in SBDS are associated with Schwachman-Diamond Syndrome. Nat Genet. 2003; 33(1):97–101.Google Scholar

Wong, CC, Traynor, D, Basse, N, et al. Defective ribosome assembly in Shwachman-Diamond syndrome. Blood. 2011; 118(16):4305–4312.Google Scholar

Ballmaier, M, Germeshausen, M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Semin Thromb Hemost. 2011; 37(6):673–681.Google Scholar

Ballmaier, M, Germeshausen, M, Schulze, H, et al. C-MPL mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001; 97:139–146.Google Scholar

Al-Qahtani, . Congenital amegakaryocytic thrombocytopenia: a brief review of the literature. Clin Med Insights Pathol. 2010; 3:25–30.CrossRefGoogle ScholarPubMed

DiMauro, S, Hirano, M. Mitochondrial DNA Deletion Syndromes. 2003 Dec 17 [Updated 2011 May 3]. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews® [Internet]. Seattle, WA: University of Washington; 1993–2014. Available from: www.ncbi.nlm.nih.gov/books/NBK1203/Google Scholar

Rotig, A, Colonna, M, Bonnefont, JP, et al. A mitochondrial DNA deletion in Pearson’s marrow pancreas syndrome. Lancet. 1989; 333:902–903.CrossRefGoogle Scholar

Cherry, AB, Gagne, KE, McLoughlin, EM, et al. Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells. 2013; 31(7):1287–1297.Google Scholar

Boxer, LA. Severe congenital neutropenia: genetics and pathogenesis. Trans Am Clin Climatol Assoc. 2006; 117:13–32.Google ScholarPubMed

Horwitz, MS, Corey, SJ, Grimes, HL, et al. ELANE mutations in cyclic and severe congenital neutropenia. Hematol Oncol Clin N Am. 2013; 27:19–41.Google Scholar

Khincha, PP, Savage, SA. Genomic characterization of the inherited bone marrow failure syndromes. Semin Hematol. 2013; 50(4):333–347.Google Scholar

Albers, CA, Newbury-Ecob, R, Ouwehand, WH, et al. New insights into the genetic basis of TAR (thrombocytopenia-absent radii syndrome). Curr Opin Genet Dev. 2013; 23(3):316–323.Google Scholar

Weiss, G, Goodnough, LT. Anemia of chronic disease. N Engl J Med. 2005; 352(10):1011–1023.Google Scholar

Cartwright, GE, Lauritsen, MA, Jones, PJ, Merrill, IM, Wintrobe, MM. The anemia of infection. I. Hypoferremia, hypercupremia, and alterations in porphyrin metabolism in patients. J Clin Invest. 1946; 25(1):65–80.CrossRefGoogle ScholarPubMed

Blanc, B, et al. Nutritional anaemias. Report of a WHO scientific group. World Health Organization Technical Report Series. 1968; 405:5–37.Google Scholar

Yip, R, Dallman, PR. The roles of inflammation and iron deficiency as causes of anemia. Am J Clin Nutr. 1988; 48(5):1295–1300. Epub 1988/11/01.Google Scholar

Guralnik, JM, Eisenstaedt, RS, Ferrucci, L, Klein, HG, and Woodman, RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004; 104(8):2263–2268.Google Scholar

Masson, C. Rheumatoid anemia. Joint Bone Spine. 2011; 78(2):131–137. Epub 2010/09/21.Google Scholar

Wilson, A, Reyes, E, Ofman, J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004; 116 Suppl 7A:44S–49S.Google Scholar

Piagnerelli, M, Vincent, JL. The use of erythropoiesis-stimulating agents in the intensive care unit. Crit Care Clin. 2012; 28(3):345–362, v. Epub 2012/06/21.Google Scholar

van Iperen, CE, van de Wiel, A, Marx, JJ. Acute event-related anaemia. Br J Haematol. 2001; 115(4):739–743. Epub 2002/02/15.Google Scholar

Sihler, KC, Napolitano, LM. Anemia of inflammation in critically ill patients. J Intensive Care Med. 2008; 23(5):295–302. Epub 2008/08/15.Google Scholar

Baer, AN, Dessypris, EN, Goldwasser, E, Krantz, SB. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol. 1987; 66(4):559–564.Google Scholar

Means, RT Jr., Krantz, SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992; 80(7):1639–1647.CrossRefGoogle ScholarPubMed

Koury, MJ, Ponka, P. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr. 2004; 24:105–131.Google Scholar

Cartwright, GE, Lee, GR. The anaemia of chronic disorders. Br J Haematol. 1971; 21(2):147–152. Epub 1971/08/01.Google Scholar

Nemeth, E, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306(5704):2090–2093.Google Scholar

Qiao, B, et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. 2012; 15(6):918–924. Epub 2012/06/12.Google Scholar

Ross, SL, et al. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab. 2012; 15(6):905–917. Epub 2012/06/12.Google Scholar

Ganz, T, Nemeth, E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematol Am Soc Hematol Educ Program. 2011; 2011:538–542. Epub 2011/12/14.Google Scholar

Schwoebel, F, et al. The effects of the anti-hepcidin Spiegelmer NOX H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013; 121(12):2311–2315. Epub 2013/01/26.Google Scholar

Wang, W, Knovich, MA, Coffman, LG, Torti, FM, Torti, SV. Serum ferritin: past, present and future. Biochim Biophys Acta. 2010; 1800(8):760–769. Epub 2010/03/23.Google Scholar

Cash, JM, Sears, DA. The anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. Am J Med. 1989; 87(6):638–644.Google Scholar

Roy, CN. Anemia of inflammation. Hematology Am Soc Hematol Educ Program. 2010; 30:276–280.CrossRefGoogle Scholar

Skikne, BS. Serum transferrin receptor. Am J Hematol. 2008; 83(11):872–85.Google Scholar

Marti-Carvajal, AJ, Agreda-Perez, LH, Sola, I, Simancas-Racines, D. Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis. Cochrane Database Syst Rev. 2013; 2:CD000332. Epub 2013/03/02.Google Scholar

Dallman, PR, Yip, R, Johnson, C. Prevalence and causes of anemia in the United States, 1976 to 1980. Am J Clin Nutr. 1984; 39(3):437–445. Epub 1984/03/01.Google Scholar

Price, EA, Mehra, R, Holmes, TH, Schrier, SL. Anemia in older persons: etiology and evaluation. Blood Cells Mol Dis. 2011; 46(2):159–165. Epub 2011/01/07.Google Scholar

Artz, AS, Thirman, MJ. Unexplained anemia predominates despite an intensive evaluation in a racially diverse cohort of older adults from a referral anemia clinic. J Gerontol A Biol Sci Med Sci. 2011; 66(8):925–932. Epub 2011 Jun 9.Google Scholar

Voulgarelis, M, Kokori, SI, Ioannidis, JP, Tzioufas, AG, Kyriaki, D, Moutsopoulos, HM. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. Ann Rheum Dis. 2000; 59(3):217–222.Google Scholar

Martinez-Lado, L, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011; 90(3):186–193. Epub 2011/04/23.Google Scholar

Vincent, JL, et al. Anemia and blood transfusion in critically ill patients. J Am Med Assoc. 2002; 288(12):1499–1507. Epub 2002/09/24.Google Scholar

Sekeres, MA, Schoonen, WM, Kantarjian, H, List, A, Fryzek, J, Paquette, R, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. Journal of the National Cancer Institute. 2008; 100(21):1542–1551.Google Scholar

Rollison, DE, Howlader, N, Smith, MT, Strom, SS, Merritt, WD, Ries, LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1):45–52.Google Scholar

Goldberg, SL, Chen, E, Corral, M, Guo, A, Mody-Patel, N, Pecora, AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010; 28(17):2847–2852.Google Scholar

Pedersen-Bjergaard, J, Daugaard, G, Hansen, SW, Philip, P, Larsen, SO, Rorth, M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet. 1991; 338(8763):359–363.Google Scholar

Liew, E, Owen, C. Familial myelodysplastic syndromes: a review of the literature. Haematologica. 2011; 96(10):1536–1542.Google Scholar

Hoffman, R. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2009:xxvii, 2523.Google Scholar

Hsu, AP, Sampaio, EP, Khan, J, Calvo, KR, Lemieux, JE, Patel, SY, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011; 118(10):2653–2655.Google Scholar

Bejar, R, Levine, R, Ebert, BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011; 29(5):504–515.Google Scholar

Walter, MJ, Shen, D, Ding, L, Shao, J, Koboldt, DC, Chen, K, et al. Clonal architecture of secondary acute myeloid leukemia. The New England Journal of Medicine. 2012; 366(12):1090–1098.Google Scholar

Haase, D, Germing, U, Schanz, J, Pfeilstocker, M, Nosslinger, T, Hildebrandt, B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007; 110(13):4385–4395.CrossRefGoogle ScholarPubMed

List, A, Dewald, G, Bennett, J, Giagounidis, A, Raza, A, Feldman, E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England Journal of Medicine. 2006; 355(14):1456–1465.Google Scholar

Bejar, R, Stevenson, KE, Caughey, BA, Abdel-Wahab, O, Steensma, DP, Galili, N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012; 30(27):3376–3382.Google Scholar

Papaemmanuil, E, Gerstung, M, Malcovati, L, Tauro, S, Gundem, G, Van Loo, P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616–3627; quiz 99.Google Scholar

Haferlach, T, Nagata, Y, Grossmann, V, Okuno, Y, Bacher, U, Nagae, G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28(2):241–247.CrossRefGoogle ScholarPubMed

Bejar, R, Stevenson, K, Abdel-Wahab, O, Galili, N, Nilsson, B, Garcia-Manero, G, et al. Clinical effect of point mutations in myelodysplastic syndromes. The New England Journal of Medicine. 2011; 364(26):2496–2506.Google Scholar

Yoshida, K, Sanada, M, Shiraishi, Y, Nowak, D, Nagata, Y, Yamamoto, R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64–69.Google Scholar

Christiansen, DH, Andersen, MK, Pedersen-Bjergaard, J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2001; 19(5):1405–1413.CrossRefGoogle ScholarPubMed

Greenberg, PL, Tuechler, H, Schanz, J, Sanz, G, Garcia-Manero, G, Sole, F, et al. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016; 128(16):2096–2067.Google Scholar

Valent, P. Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2012; 2012:485–491.Google Scholar

Arber, DA, Orazi, A, Hasserjian, R, Thiele, J, Borowitz, MJ, Le Beau, MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391–2405.Google Scholar

Bejar, R, Greenberg, PL. The impact of somatic and germline mutations in myelodysplastic syndromes and related disorders. Journal of the National Comprehensive Cancer Network. 2017; 15(1):131–135.Google Scholar

Network NCC. National Comprehensive Cancer Network Guidelines: Myelodysplatic Syndromes Version 2.2014 275 Commerce Drive, Suite 300, Fort Washington, PA 190342013 Version 2.2014: Available from: www.nccn.org.Google Scholar

Cargo, CA, Rowbotham, N, Evans, PA, Barrans, SL, Bowen, DT, Crouch, S, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood. 2015; 126(21):2362–2365.Google Scholar

Kwok, B, Hall, JM, Witte, JS, Xu, Y, Reddy, P, Lin, K, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015; 126(21):2355–2361.Google Scholar

Greenberg, P, Cox, C, LeBeau, MM, Fenaux, P, Morel, P, Sanz, G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079–2088.CrossRefGoogle ScholarPubMed

Garcia-Manero, G, Shan, J, Faderl, S, Cortes, J, Ravandi, F, Borthakur, G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2008; 22(3):538–543.Google Scholar

Bejar, R, Stevenson, KE, Caughey, BA, Abdel-Wahab, O, Steensma, DP, Galili, N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology. 2012; 30(27):3376–3382.CrossRefGoogle ScholarPubMed

Greenberg, PL, Tuechler, H, Schanz, J, Sanz, G, Garcia-Manero, G, Sole, F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454–2465.CrossRefGoogle ScholarPubMed

Greenberg, PL, Stone, RM, Al-Kali, A, Barta, SK, Bejar, R, Bennett, JM, et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2017; 15(1):60–87.Google Scholar

Hellstrom-Lindberg, E, Gulbrandsen, N, Lindberg, G, Ahlgren, T, Dahl, IM, Dybedal, I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology. 2003; 120(6):1037–1046.CrossRefGoogle ScholarPubMed

Greenberg, PL, Sun, Z, Miller, KB, Bennett, JM, Tallman, MS, Dewald, G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009; 114(12):2393–2400.Google Scholar

Passweg, JR, Giagounidis, AA, Simcock, M, Aul, C, Dobbelstein, C, Stadler, M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care–SAKK 33/99. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011; 29(3):303–309.Google Scholar

Malcovati, L, Porta, MG, Pascutto, C, Invernizzi, R, Boni, M, Travaglino, E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005; 23(30):7594–7603.Google Scholar

Cutler, CS, Lee, SJ, Greenberg, P, Deeg, HJ, Perez, WS, Anasetti, C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104(2):579–585.Google Scholar

Koreth, J, Pidala, J, Perez, WS, Deeg, HJ, Garcia-Manero, G, Malcovati, L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013; 31(21):2662–2670.Google Scholar

Silverman, LR, Demakos, EP, Peterson, BL, Kornblith, AB, Holland, JC, Odchimar-Reissig, R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2002; 20(10):2429–2440.Google Scholar

Kadia, TM, Jabbour, E, Kantarjian, H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Seminars in Oncology. 2011; 38(5):682–692.Google Scholar